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ABSTRACT
OBJECTIVES: Many symptoms associated with concussion are also associated with
symptoms related the menstrual cycle, for example headache, nausea, and fatigue. This
study sought to investigate the relationship between these symptoms at different points in
the menstrual cycle to determine if it is appropriate to compare baseline symptom reports
obtained in one menstrual phase with post-concussive symptom reports from another.
METHODS: 17 female and 11 male participants recruited from the psychology
participant pool were given a measure of post-concussive symptoms (PCSS) and a
measure of mood and stress symptoms (DASS). Females were also given a menstrual
symptom questionnaire (DSRS). Participants completed the questionnaires on two
occasions, two weeks apart. Females completed the questionnaires once during the
follicular phase of their menstrual cycle and once during the luteal phase.
RESULTS: No significant differences between female and male reports on the PCSS or
DASS were found. Symptoms on the DASS were found to decrease over time. PCSS and
DSRS scores in females were significantly correlated at both time points, but more
strongly correlated during the luteal phase. PCSS scores over time were correlated in
male but not female participants.
CONCLUSIONS: The absence of significant results indicating an increase in the number
and severity of symptoms experienced by females during the luteal phase suggests that
there may be no need to control for menstrual phase at baseline. However, given that
female PCSS scores were not correlated between times 1 and 2, type of symptoms may
vary even if overall number and severity do not.
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CHAPTER 1
RELEVANCE AND IMPORTANCE
Mild traumatic brain injuries (mTBI) have been identified as an important health
problem deserving of more attention in order to prevent the incidence of new injuries
(Upshur & Echlin, 2014). In the context of sports injuries, mTBIs are commonly referred
to as concussions and generally represent mTBIs of mild severity. The incidence of
sports-related concussion is estimated to be between 1.6 and 3.8 million annually in the
United States (Langlois, Rutland-Brown & Wald, 2006). It is usually defined as trauma to
the head resulting in a Glasgow Coma Scale score of 13-15, less than 24 hours of posttraumatic amnesia, and no evidence of intracranial abnormality on CT scan (Tellier et al.,
2009). Individuals who sustain mTBI often report a constellation of symptoms, which can
include symptoms such as headache, nausea, fatigue, irritability, sleep disturbance, mood
swings, and anxiety, among others (King, 1997; McCrea et al., 2003; Ryan & Warden,
2003; Wiebe, Comstock & Nance, 2011). Although not severe in nature, these symptoms
can interfere with the daily lives of those who experience them. In addition, there is
evidence that sustaining multiple mTBIs may predispose individuals to developing a
myriad of other serious health problems, including early-onset dementia, substance-use
disorders, and other mental illness, which further illustrates the importance of researching
the effects of mTBI in order to prevent new incidences (Canadian Institutes of Health
Research, 2012). Although the vast majority of individuals who sustain a mTBI will
recover within weeks to months (Frommer et al., 2006; Guskiewicz et al., 2003; McCrea
et al., 2003), there is an increased risk of prolonged symptoms and for long-term
consequences on health as well as on cognitive and emotional functioning after sustaining
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a mTBI (Frommer et al., 2006; Guskiewicz et al., 2003; Meehan, Mannix, Stracciolini,
Elbin, & Collins, 2013). Further, the odds of suffering prolonged symptoms after a mTBI
are increased in those who report more symptoms after injury compared with those who
report an average number of symptoms (Meehan et al., 2013).
Sex Differences in mTBI
There have been differences observed between male and female athletes after
incurring mTBIs. The rates of injury of mTBI in female athletes is higher compared to
male athletes (Covassin, Swanik & Sachs, 2003). In addition, females have been shown
to suffer from more adverse effects after mTBI than males, including being cognitively
impaired approximately 1.7 times more frequently (Broshek, Kaushik, Freeman,
Erlanger, Webbe, & Barth, 2003), as well as experiencing more severe and prolonged
symptoms (King, 2014). The reason that females experience higher rates of and worse
outcome after mTBI is unclear, but there are multiple potential contributors. For example,
females are smaller in size and generally have weaker neck muscles then men (Covassin,
Swanik & Sachs, 2003). There is also evidence that the influence of the female sex
hormones, particularly estrogen and progesterone, play a role in somatic, affective, and
cognitive symptoms reported (King, 2014). For example, estrogen is related to migraines
and anxiety and progesterone is involved with maintaining regular sleep patterns and
learning novel information (Andersen, Bittencourt, Antunes & Tufik, 2006; MacGregor,
Frith, Ellis, Aspinall & Hackshaw, 2006; Seeman, 1997).
Despite noted sex differences after mTBI there have been many contradictory
findings as to whether or not females and males differ at baseline in terms of symptoms
and neuropsychological ability (Covassin, Schatz & Swanik, 2007; Mihalik, Ondrak,
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Guskiewicz & McMurray, 2009; Valovich McLeod, Bay, Lam & Chhabra, 2012). The
Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) test is a
commonly used baseline symptom and cognition measure. The manual indicates that
there are slight gender differences in the normative data for the various subtests, which
include verbal memory, visual memory, visual motor speed and reaction time (ImPACT
Application, Inc., 2011). The manual also presents means and standard deviations for the
Post-Concussion Symptom Scale (described in more detail below), which show slight but
statistically insignificant differences between males and females at different ages
(ImPACT Application, Inc., 2011). Covassin et al. (2007) also found no significant
difference between the sexes on any composite scores on the ImPACT or Total symptom
score. Another study found that female athletes endorse significantly more symptoms
with mild severity at baseline than males (Covassin, Swanik, Sachs, Kendrick, Schatz,
Zillmer & Kaminaris, 2006). To further complicate things, Frommer et al. (2011) found
that after concussion, females report more neurobehavioural and somatic symptoms (i.e.,
drowsiness and sensitivity to noise) and that males report more cognitive symptoms (i.e.,
amnesia, confusion/disorientation). Frommer et al. go on to recommend that symptoms
experienced after potential head injuries reported by females, even though the
presentation may be different from the presentation that has been typically seen in males,
should be linked to the possibility of incurring a concussion rather than assuming some
other neuropsychological cause (2011).
One potential confound in this research may be the fluctuating hormonal changes
in females associated with their menstrual cycles. It is widely known that females of
reproductive age experience hormonal fluctuations over the course of approximately 28
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days in relation to their menstrual cycles. Menstrual cycle symptoms are experienced by
20-40% of women and many of the same symptoms that are present in post-concussive
syndrome are also associated with menstrual cycle phase (Archer, 2006). Despite the high
incidence of menstrual cycle symptoms experienced by women, research investigating
the effect of menstrual cycle phase on baseline concussion symptom reporting is limited.
The Menstrual Cycle and Hormonal Influences
There is strong evidence to support the claim that the female sex hormones
estrogen and progesterone influence mood and mental function, including many of the
symptoms that are assessed during athlete baseline assessments, such as difficulty
concentrating, irritability, and headache, to name a few (Farage, Osborn & MacLean,
2008). Hormonal fluctuations over the menstrual cycle are suggested to modulate
emotion and cognition through dopaminergic transmission (Sacher et al., 2013). There is
evidence that varying concentrations of female sex hormones, estrogen and progesterone
in particular, over the course of different menstrual cycle phases influence a number of
brain structures including the striatum, hippocampus, thalamus, hypothalamus, insula,
amygdala, frontal cortex (specifically, the inferior and middle frontal gyri), anterior
cingulate cortex, and parietal areas that may all play a role in the presence of mood and
cognitive symptoms (Hines, 2010; Sacher, Okon-Singer & Villringer, 2013; Fanselow &
Dong, 2010; Steiner, 2003; Toffoletto, Lanzenberger, Gingnell, Sundström-Poromaa &
Comasco, 2014).
The varying concentrations of female sex hormones influence the presence of
symptoms differently over the course of the month (Sacher et al., 2013). The menstrual
cycle is divided into phases: the follicular phase, ovulation, and the luteal phase. The
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follicular and luteal phases consist of varying concentrations of the female sex hormones,
including estrogen and progesterone, which can be seen in Figure 1 (Terner & De Wit,
2006; Sacher et al., 2013). The follicular phase refers to the time between the onset of
menses and ovulation and the luteal phase refers to the period between ovulation and the
onset of menses (Sacher et al., 2013). The menstrual cycle typically lasts about 28 days;
day 1 refers to the onset of menses, which lasts approximately until day 7, and the
premenstrual period lasts between days 22 and 28 (Fraser, 1985). There is evidence that
eumenorrheic females (those who are experiencing normal or regular menstrual cycles
and who are not taking any hormone-influencing medications) experience different brain
activation patterns between the follicular and luteal phases than those females who are
not eumenhorrheic (Toffoletto et al., 2014).
Progesterone concentrations are very low during menses and the early part of the
follicular phase, then rise after ovulation, peaking mid-luteal phase, and falling rapidly
before menses (Terner & De Wit, 2006; Sacher et al., 2013). Estrogen concentrations are
also low during menses and the early part of the follicular phase, rise in the middle and
late follicular phase with a peak around ovulation, remain moderate during the luteal
phase, and decrease sharply before the onset of menses (Terner & De Wit, 2006). Most
studies analysing changes related to the menstrual cycle compare performance during the
late follicular phase (when progesterone concentrations are low and estrogen
concentrations are high) with the late luteal phase (when progesterone concentrations are
high and estrogen concentrations are low; Sacher et al., 2013).
Neurocognitive tasks for which women have been shown to perform better than
men, such as verbal memory, are most clearly differentiated between the sexes when

5

MENSTRUAL PHASE & PCS SYMPTOM REPORTING
females’ estrogen concentrations are higher: during the luteal phase (Warren, Gurvich,
Worsley & Kulkarni, 2014). Conversely, high progesterone concentrations have been
observed to have negative effects on neurocognitive performance (Warren et al., 2014).

Figure 1. Hormonal fluctuations over the menstrual cycle. This Wikipedia and
Wikimedia Commons image is from the user Chris 73 and is freely available at
http://commons.wikimedia.org/wiki/Image:MenstrualCycle.png under the creative
commons cc-by-sa 2.5 license.
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Estrogen. The presence of female sex hormones, estrogen in particular, is
associated with a number of somatic and affective symptoms. For example, falling
concentrations of estrogen after a period of sustained estrogen presence is associated with
migraines (MacGregor et al., 2006). Sixty percent of women who experience migraines
link them to their menstrual cycle, but only about 8 to 14% of these are actually related to
menstrual cycle phase (Case & Reid, 1998). Estrogen has also been shown to up-regulate
GABA receptors, which implicates it with increasing levels of anxiety and depression
(Seeman, 1997). The presence of estrogen itself has not been found to directly dampen
mood, but the cyclical nature of estrogen presence in the brain and the resulting on-andoff nature of the binding of estrogen receptors has been suggested to make women more
vulnerable to stress (Seeman, 1997). It is speculated that the recurrent withdrawal of
estrogen may interfere with the ability to neutralize the effects of glucocorticoids released
during periods of stress (Seeman, 1997).
Progesterone. The effects of progesterone have been less studied than those of
estrogen. It is involved in a number of processes throughout the body, including normal
sleep, mood, appetite, learning, and memory (Andersen et al, 2006).
Follicle-Stimulating Hormone and Luteinizing Hormone. These hormones are
produced by the pituitary gland. Follicle-stimulating hormone causes secretions of
estrogen by stimulating the growth of follicles in the ovaries, and both work to cause
ovulation and the release of estrogen and progesterone (Bowen, 2004).
Overall, the influence of fluctuating sex hormones in women is known to
influence many brain regions, resulting in changes to cognitive and affective processing
over the course of the menstrual cycle, including levels of anxiety, depression, and
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somatic complaints (Sacher et al., 2013; Seeman, 1997; Toffoletto et al., 2014). However,
there are inconsistent findings about the nature and existence of specific mood changes
between menstrual cycle phases in the literature (Romans, Clarkson, Einstein, Petrovic &
Stewart, 2012). Some of these changes, which take place near the end of the menstrual
cycle, are often referred to as premenstrual syndrome (PMS). There is no one universally
agreed upon definition of PMS and it affects women differently. As such the various
studies of symptoms may focus on different aspects associated the syndrome. There are
over 60 instruments used to measure various symptoms related to the menstrual cycle,
and many only focus on increases in the negative symptoms (e.g. irritability) rather than
including information about positive symptoms (e.g. happiness) that may fluctuate over
the course of the menstrual cycle (Romans et al., 2012). One study of experimentally
naïve women found increases of anxiety, irritability, depression, and tension but lower
reports of fatigue, confusion, sleep problems, and depression in the premenstrual phase
(Parlee, 1982). Another study found that 70% of women complained of irritability,
decreased morale, depression, and fatigue premenstrually (Paulson, 1961). Choi and
McKeown’s study of PMS symptoms revealed than many women subjectively
acknowledge the experience of some symptoms, but do not believe that their symptom
presentations are severe enough to be considered full-blown cases of PMS (1997).
Related to there being no one universally agreed upon definition, studies have
also studied the presence of symptoms at slightly different time points within the
menstrual cycle. Some research has indicated that the symptoms associated with PMS do
not end as soon as menstruation occurs, but rather linger for two or three days (Romans et
al., 2012).
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Hormones and mTBI
The relationship between menstrual phase and outcome following mTBI is
unclear. However, it has been observed that during their childbearing years females are
more likely to report greater symptoms after incurring mTBI than males, suggesting the
possibility that estrogen or progesterone production disruption may influence the
presence of symptoms (Bazarian, Blyth, Mookerjee & McDermott, 2010). In fact, injury
to the anterior pituitary gland may result in the disruption of endogenous estrogen and/or
progesterone production, resulting in withdrawal of those hormones (Bazarian et al.,
2010). High concentrations of progesterone have been linked with a reduction of neural
impairment after mTBI whereas the findings on estrogen’s influence have been mixed
(Broshek et al., 2005).
Lastly, there are potentially confounding factors to consider when examining the
role of menstrual cycle phase on symptom reporting in athletes, such as use of oral
contraceptives and level of physical activity. These factors have been shown to influence
menstrual cycle related symptomatology, as well as general symptom reporting and
mood, and will be discussed next.
Oral Contraceptive Use
The use of oral contraceptives is an important consideration for research on the
effects of sex hormones in women. A Canadian study found that 43% of women of
reproductive age use oral contraceptives (Black, Yang, Wu Wen, Lalonde, Guilbert, &
Fisher, 2009). Oral contraceptives prevent pregnancy by influencing the hypothalamicpituitary-ovarian axis and are the most common medication prescribed to women of
reproductive age (Archer, 2006). They have been found to reduce the symptoms
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associated with menses, such as migraines, fatigue, and depression (Yonkers, O’Brien &
Eriksson, 2008). Eumenorrheic females have been shown to endorse a higher number of
symptoms and report an increased symptom severity score compared to females using
oral contraceptive pills on baseline concussion testing (Mihalik, 2009). As the use of oral
contraceptives reduces symptoms in women who use them, it is important to determine
whether women are using them when research evaluating symptom prevalence and/or
severity is being conducted.
Physical Activity
Physical activity has been shown to reduce the number and severity of general
symptoms reported (Choi & Salmon, 1995) as well as PMS symptoms (Scully, Kremer,
Meade, Graham & Dudgeon, 1998). Further, symptoms associated with menstruation
have been shown to be reduced with the implementation of an exercise-training program
(Koushkie Jahromi, Gaeini & Rahimi, 2008). Physical fitness levels have also been
shown to influence the number of symptoms experienced, with higher levels of physical
fitness being associated with fewer reported symptoms (Mrazik, Naidu, Lebrun, Game &
Matthews-White, 2013). In particular, physical activity has been linked with a reduction
in depression intensity (Nabkasorn, 2005). Therefore, it is important to consider that level
of physical fitness may influence the number and severity of symptoms endorsed by an
individual.
The Current Study
In sports-related concussion management programs, athletes are often assessed
pre-season in order to establish a baseline level of cognitive performance as well as a
baseline level of symptom reporting. It is important to consider symptoms at baseline in
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order to assess whether or not the individual is ready to re-engage in physical activity,
such as playing in a sporting event, after incurring a mTBI. Engaging in physical activity
before the brain has had sufficient time to heal after injury can result in more severe postconcussive symptoms and a longer recovery period (Kissick & Johnston, 2005). In order
to ensure that female athletes are ready to re-engage in physical activity without incurring
further insult to their brains it is important to understand the relationship between the
presence of symptoms at baseline and how they may vary over the course of the
menstrual cycle.
The motivation for this study comes from the fact that many symptoms of PCS
and PMS overlap. This study will examine how the symptoms experienced by women
during different phases of the menstrual cycle overlap and relate to the symptoms
typically associated with incurring a concussion by examining symptom prevalence over
different stages of the menstrual cycle. It is important to understand the non-concussion
related causes of these symptoms in athletes in order to help us better understand which
symptoms are due to concussion versus other sources after a head injury is incurred. This
study seeks to determine how appropriate it is to compare baseline symptom reports with
post-concussive symptom reports of female athletes during different menstrual phases.
Hypotheses
1. It was hypothesized that the number and severity of symptoms reported on a postconcussion symptom report commonly used for baseline assessments would
correlate highly with the number and severity of symptoms reported on a measure
of menstrual symptoms in females in the follicular phase and again in the luteal
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phase of their menstrual cycles, due to the overlapping nature of many of the
symptoms experienced in both conditions.
2. It was hypothesized that women will experience fewer and less severe affective
and somatic symptoms at their first testing session, which occurred during the
follicular phase, and more affective and somatic symptoms during the second
testing session, which occurred in the luteal phase, as concentrations of both
estrogen and progesterone are increased compared with menstrual phase and
symptoms typically decline at the onset of menstruation (Backstrom et al., 1983).
Further, it is hypothesized that the number and severity of symptoms reported by
males will remain constant at both measurement points.
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CHAPTER 2
DESIGN AND METHODOLOGY
Participants
Participants for this study were recruited from the psychology participant pool at
the University of Windsor. The participant pool is composed of undergraduate students
who elect to take part in psychological research in exchange for extra credit in eligible
courses. A total of 44 participants (31 female) were recruited. Despite the advertisement
for the study saying that only women who have experienced a regular menstrual cycle
(lasting approximately 28 days, for at least the past two months) may participate, four
female participants reported irregular menstrual cycles and thus were eliminated from the
analyses. Five women were deleted from analysis as they reported on the questionnaires
being in a different place in their menstrual cycle than what they told the experimenter.
Two females were fasting for Ramadan at the time of their second session (one of which
was already eliminated for reporting an irregular cycle), and were eliminated from
analyses due to the potential confounding effects of fasting on the symptom reports. One
additional female had to be deleted due to an administration error resulting in her
menstrual cycle data never being collected. Due to the fact that this was a repeated
measures study, significantly more participants than were needed for analysis were
sought for recruitment in an attempt to account for attrition and potential noise or
invalidity in the data collected. Nonetheless, fewer than the desired number of
participants signed up for the study. Three female participants and two male participants
had to be eliminated from the analysis due to attrition. Thus, a total of 17 female and 11
male participants were included in analyses.
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Participants received reminder emails for the study by the participant pool system
the night before their appointments. Participants were incentivised with the awarding of
half of a bonus point each time they spent half an hour completing the surveys, which
they were able to use toward their final grade on any eligible course, as per the
participant pool regulations.
The risks of participating in this study were minimal and fully explained to
participants in the consent form. Questions about mood were collected as part of this
study, and sometimes discussing the presence of mood symptoms can draw attention to
them, resulting in psychological distress, so the questionnaires were followed with a page
that included information for accessing community mental health resources for all
participants.
Measures
Demographics. Participants were asked to record their age, gender, and level of
education completed. This information was used for descriptive purposes and was
collected using Fluid Surveys. Female participants were also asked to confirm that they
have regular cycles and to record the date that their last menstrual period commenced in
order to ensure that they began the study at approximately the same place in their
menstrual cycle, approximately 5-7 days after the onset of their last period.
Post-Concussion Symptom Scale. The Post-Concussive Symptom Scale (PCSS;
ImPACT Application Inc., 2011) questionnaire was used to evaluate the presence of
some typical symptoms associated with post-concussive syndrome, such as headache,
fatigue, drowsiness, and difficulty concentrating (see Appendix A for the symptom list).
The PCSS is a self-report measure which uses a 7-point Likert scale ranging from “0 - not
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experiencing” to “6 - severe” to rate the presence of 22 symptoms. Participants are asked
to rate the severity of each symptom as they are currently experiencing it. A Total
symptom score can also be calculated though combining the report of the all symptoms
measured. A series of psychometric analyses demonstrated that Immediate PostConcussion Assessment Testing (ImPACT®) Test, from which the PCSS is taken, has
adequate concurrent, divergent, and convergent validity for clinical inferences of postconcussion outcome in amateur athletes (ImPACT Application Inc., 2007). Adequate
internal consistency of the PCSS has been reported (α = 0.88 to 0.94) (McLeod & Leach,
2012). The meaningful change score has been reported to be 6.8 points, indicating that a
difference of approximately 7 points on the PCSS Total score at the second instance of
responding to the questionnaire suggests that there is a significant difference in the
number of symptoms that the person is experiencing (McLeod & Leach, 2012). Testretest reliability has also been shown to be adequate (r = 0.8) (ImPACT Application Inc.,
2011).
Depression Anxiety Stress Scales. The severity of depressive, anxiety, and stress
symptoms was evaluated using the Depression Anxiety Stress Scales (DASS; Lovibond
& Lovibond, 1995). The DASS questionnaire can be found in Appendix B. The DASS is
a self-report measure that consists of 42 questions answered on a Likert scale, which
ranges from “0 – did not apply to me at all” to “3 – applied to me very much, or most of
the time”. Thus higher scores correspond with more severe symptoms. Participants are
asked to rate how much the statement applied to them over the past week. After
completion by the participants, the scale is divided into Depression, Anxiety, and Stress
composite scores. The Depression scale evaluates the presence of symptoms typically
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associated with depression, including hopelessness, anhedonia, self-depreciation, and
dysphoria. Sample items from the Depression scale include statements like “I felt that I
had lost interest in just about everything” and “I felt I wasn't worth much as a person”.
The Anxiety scale assesses situational anxiety and autonomic arousal. Sample items from
the Anxiety scale include “I was aware of the action of my heart in the absence of
physical exertion (e.g., sense of heart rate increase, heart missing a beat)” and “I was
worried about situations in which I might panic and make a fool of myself ”. The Stress
scale assesses levels of chronic, non-specific levels of arousal, including becoming easily
agitated, difficulty relaxing, and irritability. Sample items from the Stress scale include “I
found it hard to wind down” and “I tend to overreact to situations”. The DASS has a
reputation for distinguishing anxiety, depression, and stress well and has adequate
internal consistency and concurrent validity, with Cronbach's alphas for the Depression,
Anxiety, and Stress subscales shown to be .97, .92, and .95, respectively (Antony,
Bieling, Cox, Enns & Swinson, 1998). Internal consistency and temporal stability of the
measure has been found to be adequate in clinically depressed samples (Page, Hooke &
Morrison, 2007). The DASS has been used in clinical research of TBI and is described as
a useful tool for measuring emotional status following an acquired brain injury (Dahm,
Wong & Ponsford, 2013; Ownsworth, Little, Turner, Hawkes & Shum, 2008).
Physical Activity Scale. The Physical Activity Scale (PAS; Aadahl & Jørgensen,
2003) was used to assess participants’ levels of physical activity during the previous
week. The PAS was translated to English from a Danish version of the scale and has been
shown to exhibit adequate face and concurrent validity (Aadahl & Jørgensen, 2003). It
was selected due to its ease of administration. The scale can be found in Appendix C. To
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complete the PAS, participants are asked to estimate the amount of time they spend on an
average day engaging in tasks of nine different intensity levels. These nine different
levels range from tasks involving very low energy expenditure, i.e. “sleep, rest”, to high
levels of energy expenditure, i.e. “running, racing on bicycle, playing soccer, handball,
or tennis”. The nine levels are associated with different levels of metabolic equivalents
(MET) which estimate energy expenditure based on intensity of activity (Aadahl &
Jørgensen, 2003). For each activity level measured, the MET value is multiplied by time
spent on that activity, which are then added together to represent physical activity level
on an average day (Aadahl & Jørgensen, 2003).
Daily Symptom Rating Scale. Female participants recorded the presence and
severity of common menstrual symptoms through rating the severity of their experience
of a series of symptoms at each testing session. The symptoms were measured using the
Daily Symptom Rating Scale (DSRS; Taylor, 1979), which can be found in Appendix D.
The DSRS measures 17 symptoms typically associated with changes over the menstrual
cycle and can be divided into somatic and affective indices. Symptoms were rated on a 5point Likert scale to measure the severity of the symptoms which ranges from “0 = not at
all” to “5 = a very large amount”. The DSRS was constructed from questions used on
other menstrual symptom questionnaires and has been shown to exhibit adequate testretest reliability, with all coefficients above 0.8 (Haywood, Slade & King, 2002).
Criterion validity was also assessed through correlational analysis of four criteria:
whether the woman had ever consulted a doctor for her symptoms, the number of tablets
taken in premenstrual week, self-rating of symptom severity and estimation of severity in
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relation to most women, which all significantly correlated with the DSRS Total,
Affective, and Somatic scores (Haywood, Slade & King, 2002).
Menstrual Phase. Women were instructed to attend their first testing session
approximately 5-7 days after the onset of their last menstrual cycle. This testing session
took place during participants’ follicular phase. The women then returned 14 days later
for their second testing session, when they were expected to be in the midst of their luteal
phase, when progesterone concentrations are high and estrogen concentrations are lower.
Procedure
Participants signed up for the study through the participant pool at the University
of Windsor. Females and males signed up for separate studies on the participant pool so
that the researcher had the ability to cap the number of females and/or males if the
desired number of participants were reached. The research was conducted in person in
Dr. Abeare’s laboratory. The consent form, demographic questions, and questionnaires
were presented online using Fluid Surveys. Informed consent was first obtained from all
participants. Following their consent, all participants entered demographic information,
including age, gender, and level of education. Females were also asked to disclose the
date of the onset of their last menstrual period in order to confirm that they were
commencing the study at the desired time during their menstrual cycle, as well as confirm
that they have experienced a regular cycle (lasting 21 to 35 days for at least the past three
months, as suggested by the Mayo Foundation for Medical Education and Research,
2016). Females were also asked do disclose if they currently use any form of hormonal
contraception. Participants then completed the PAS, PCSS, and DASS questionnaires, the

18

MENSTRUAL PHASE & PCS SYMPTOM REPORTING
order of which was randomized for each participant. Females also filled out the DSRS,
which was presented in a randomized order among the other questionnaires.
The sessions took approximately twenty minutes to complete. Each participant
was asked to complete the battery again at the same time of day two weeks later.
Participants were emailed by the participant pool to remind them of their second
appointment. They were awarded half of a bonus point each time they completed the
surveys that went towards their final grade in any eligible course, as per the participant
pool regulations. Female participants were asked to complete the first survey
approximately 5-7 days after the onset of their last menstrual cycle and male participants
were allowed to begin participation on any day they chose, as they do not have the same
monthly fluctuations in hormones that females do.
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CHAPTER 3
DATA ANALYSES AND RESULTS
Screening and analyses of the data were conducted using IBM SPSS Statistics
Version 22. Data cleaning was completed by removing participants who did not fit the
inclusion criteria. Finally, assumptions of statistical tests were assessed, including
Shapiro-Wilk test, and kurtosis and skewness values for normality, and Levene’s test for
homogeneity of variance. Correlational analyses were conducted to examine the
relationship of the PCSS and DSRS over time in the female participants. A series of 2
(time) x 2 (sex) mixed factorial ANOVAs were conducted using the various measures in
order to test differences in symptom reports in both sexes over time.
Power
An a priori power analysis was conducted using the program G*Power, a free
program that allows a priori power estimates to be conducted, to determine the required
sample size for analysis. A power of .80, alpha value of .05, and effect size of 0.3859
were specified for the power analysis. The effect size of 0.3859 was estimated based on
the findings of Gallant, Hamilton, Popiel, Morokoff and Chakraborty (1991) with respect
to the effects of menstrual cycle phase on daily mood and symptoms. A sample size 18
participants of each gender was indicated. Unfortunately, this sample size was not
attained and thus many of the analyses conducted had insufficient power.
Data Screening
Before any further analyses were conducted, data was assessed for missingness.
There were no instances of missing data on the DSRS or DASS questionnaires. One
female participant was given the wrong Fluid Surveys link, and thus demographic
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information related to her menstrual phase was never collected. This participant was
deleted from analyses as her menstrual phase and regularity could not be verified. One
male participant did not complete the PCSS correctly at time 1 and thus his scores were
not included in analyses that involved the PCSS.
The PAS data was examined, and it was found that most of the participants did
not accurately rate the number of hours they spent doing the different levels of activity, as
many of their responses did not add up to 24 hours. As such, the amount of time spent
doing various activity levels and their MET equivalents were calculated, and then that
score was prorated to account for 24 hours to yield the PAS Total score.
Visual inspection of box plots indicated that there were potential outliers on some
of the questionnaires. Z scores were calculated for each questionnaire at each time point.
There was one participant with a Z score of 3.10 on PCSS Total score at time 1, another
participant with a DASS Anxiety Z score of 2.98 at time 2 and one other participant with
a DASS Stress Z score of 2.73 at time 2. All other Z scores on all questionnaires or
subscales were within 2.5 standard deviations of the means. It was decided to not remove
these potential outliers as the sample size was already small, and also because these
participants may represent variability in the population that is meaningful.
Two of the items on the PCSS and the DSRS are the exact same symptom.
Correlational analyses of these items were evaluated between the two time points as a
measure of validity. The item “headache” was positively correlated at the p < 0.01 level
on both measures, at both time points (r = 0.876 and r = 0.845 at time 1 and 2,
respectively). The item “irritability” was positively correlated at the p < 0.01 level on
both measures at time 2 (r = 0.845), but it was not significantly correlated between the

21

MENSTRUAL PHASE & PCS SYMPTOM REPORTING
measures at time 1 (r = 0.188). This suggests that there may be some inconsistencies in
the data at time 1 threatening the validity, so findings should be interpreted with caution.
Assumptions
Originally, the use of a repeated measures multivariate analysis of covariance
(MANCOVA) was planned. However, due to the small sample size and resulting lack of
power, the covariance pieces of the analyses were not conducted. Thus, the assumptions
of a mixed factorial analysis of variance (ANOVA) were tested, which include normality,
independence of observations, and homogeneity of variance.
To investigate normality of the data, Shapiro-Wilk tests, visual inspection of
scatterplots, and through examination of skewness and kurtosis cut-offs (absolute values
of 2 and 3, respectively) were conducted. In the overall sample, the DASS depression
subscale at time 2 was kurtotic (value = 2.47). In analysis of the females only, DASS
Anxiety at time 2 was kurtotic (value = 2.36). Analysis of the male participants revealed
kurtotic data on the PCSS at both time 1 and 2 (values of 4.84 and 3.42, respectively).
Shapiro-Wilks analyses also revealed significant values in the overall sample for the
DASS depression subscale at time 1, DASS Anxiety subscale at times 1 and 2, and DASS
Stress subscale and time 2 (p’s < 0.05). Analysis of the females only revealed significant
values for the same variables as the overall sample, as well as DSRS Total at time 2 and
Somatic subscale at time 2 (p’s < 0.05). In the males only PCSS Total at time 1 and 2,
and DASS depression subscale were also significant (p’s < 0.05). These results suggest
that the assumption of normality was violated.
Homogeneity of variance was confirmed through values on Levene’s test being
insignificant. It is also suggested that the highest variance value not be more than four
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times the lowest variance. For the males, the highest variance value was 569.9 on the
PCSS Total at time 1 and the lowest was only 8.2 on the DASS Anxiety subscale. In
females, the highest variance was 294.1on the PCSS at time 2 and the lowest was 14.4 on
the DASS Depression subscale at time 2. Thus, there was more variance than ideal in the
data.
Independence of observations was assumed for the sex variable, as individuals in
the male and female groups were all collected from different participants. No one person
participated more than once. As this was a repeated measures design, the second
independent variable represented time, and the same participants did participate in both
instances. Repeated measures designs have the assumption of homogeneity of covariance,
but seeing as this study only analyzed two different points in time this assumption is not
relevant, as there are not multiple variances between more than three time points.
ANOVA is known to be robust to violations if only one of the assumptions of
normality or homogeneity of variance, but in this instance both assumptions may be
violated. Ideally a non-parametric test would be used instead of ANOVA, however, nonparametric tests require larger power to show significant results. As the small sample size
in the current study limits the power of any analyses, it was decided to use ANOVA
rather than non-parametric tests.
Demographic and Descriptive Data
Descriptive statistics for demographic variables of the sample are summarized in
Table 1 below. Age and education were not found to be significantly different between
the male and female groups. Correlational analysis was used to determine whether a
relationship existed for age or education with PCSS or DASS scores. Age positively
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correlated with PCSS at time 2 (r = 0.42, p < 0.05) and level of education was negatively
correlated with the DASS Depression subscale at time 1 (r = -0.55, p > 0.01). Due to the
fact that only one dependent variable was correlated with age and one with education it
was deemed unnecessary to use age and education as covariates. Further, the small
sample size would not have allowed for analysis of covariates. Due to the restricted
ranges of age, education, and scores on the measures administered, these correlations are
likely not meaningful.
Table 1
Demographic Data Means and Standard Deviations
Age
Years of Post-Secondary School Completed
Whole Sample
(N=28)

22.50
(4.08)

2.43
(1.43)

Males
(N=11; 39.29%)

23.00
(4.67)

2.18
(1.47)

Females
(N=17; 60.71%)

22.18
(3.76)

2.59
(1.42)

Birth Control Usage. A series of mixed factorial analyses of variance
(ANOVAs) were also run using oral contraceptive use as a between subjects variable and
time as a within subjects variable to determine if there was a significant difference in the
between the women who use oral contraceptives, those who do not, and males on
symptom reports. The dependent variables examined included the PCSS, DASS
Depression subscale, DASS Anxiety subscale, and DASS Stress subscale. The analysis of
the PCSS resulted in no main effect of time [F(1, 24) = 3.45, p = 0.08], oral contraceptive
use [F(2, 24) = 0.52, p = 0.60], or their interaction [F(2, 24) = 0.14, p = 0.87]. Similarly,
there were no significant effects on the DASS Depression subscale for time [F(1, 25) =
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3.45, p = 0.08], oral contraceptive use [F(2, 25) = 0.52, p = 0.60], or their interaction
[F(2, 25) = 0.14, p = 0.87]. The DASS Anxiety subscale showed significant effects for
time [F(1, 25) = 5.63, p = 0.03], but not for oral contraceptive use [F(2, 25) = 0.17, p =
0.85] or the interaction [F(2, 25) = 0.77, p = 0.48]. The DASS Stress subscale also
indicated significant differences on time [F(1, 25) = 5.20, p = 0.03], but not contraceptive
use [F(2, 25) = 0.34, p = 0.71] or the interaction [F(2, 25) = 0.63, p = 0.54].
Mixed factorial ANOVAs were also conducted on the female participants using
oral contraceptive use as an independent variable, along with time, and using menstrual
symptoms as the dependent variable. Firstly, the DSRS Total was used, revealing no
significant effects of time [F(1, 15) = 3.62, p = 0.08], oral contraceptive use [F(1, 15) =
0.27, p = 0.61] or the interaction [F(2, 15) = 0.98, p = 0.34]. The DSRS Affective
subscale was also examined, again revealing no significant effects of time [F(1, 15) =
1.17, p = 0.30], oral contraceptive use [F(1, 15) = 0.15, p = 0.70] or the interaction [F(2,
15) = 0.04, p = 0.84]. Lastly, the DSRS Somatic subscale revealed no significant effects
of time [F(1, 15) = 3.92, p = 0.07], oral contraceptive use [F(1, 15) = 0.30, p = 0.60] or
the interaction [F(2, 15) = 1.57, p = 0.23]. Thus, oral contraceptive use did not
significantly differentiate women on the PCSS or DSRS, or on the DASS Anxiety, DASS
Depression, or DASS Stress subscales.
Physical Activity. The PAS was included with the intent to use its total score as a
measure of physical activity. It was planned to be used as a covariate in the main analysis
surrounding the second hypothesis, which stated that women would experience more and
more severe PCS symptoms during their luteal phase compared with their follicular phase
and compared with men. This was believed to be due to the fact that exercise is known to
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decrease the presence of mood and other PCS symptoms (Byrne & Byrne, 1993; Leddy et
al., 2010). Due to the small sample size in the study, which limits statistical power, and
also due to the inconsistently correct responses on the PAS, the physical activity scale
was not used as a covariate.
The PAS scores were examined to see whether they correlated with DASS
subscales, PCSS Total, or DSRS Total or subscales at the same point in time. The PAS
did not significantly correlate with any of the other measures at the same time point.
However, PAS scores at time 1 did correlate significantly with PAS scores at time 2 (r =
0.78, p < 0.01), demonstrating adequate test-retest reliability.
Menstrual and Post-Concussive Symptom Correlations
Correlational analyses were also conducted between the PCSS and DSRS at each
time point for female participants in order to examine the influence that menstrual related
symptoms have on PCSS symptom reporting. At time 1 the DSRS Total and both
subscales were all positively correlated with PCSS Total score (DSRS Total score r =
0.58, DSRS Somatic subscale r = 0.51, and DSRS Affective subscale r = 0.49, p’s <
0.05). At time 2 the DSRS Total and both subscales were also all positively correlated
with PCSS Total score (DSRS Total score r = 0.88, DSRS Somatic subscale r = 0.94, and
DSRS Affective subscale r = 0.61, p’s < 0.01). Thus the hypothesis that these two
measures would be correlated was supported. PCSS and DSRS scores were also more
highly correlated at time 2, when it was predicted that symptom reports on these
questionnaires would be higher.
Follow-up analyses revealed that the correlation between the PCSS at time 1 and
time 2 in the female participants was only 0.26, which was not significant at the p < 0.05
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level. The DSRS Total was significantly correlated between times 1 and 2 (r = 0.57, p <
0.05). The Affective subscale was significantly correlated between the two times (r =
0.70, p < 0.01) but the Somatic subscale was not (r = 0.43, p = 0.09).
Effects of Time/Menstrual Phase and Sex on Symptom Reports
The second hypothesis was tested, which predicted that women would experience
more symptoms with greater severity during the luteal phase of their menstrual cycle
compared with during their follicular phase, and compared with what men experienced
over two different time points. Table 2 shows the means and standard deviations of
scores on the measures administered.
Table 2
Means and Standard Deviations of Measures Administered
Females
Males
PAS 1
43.27
47.00
(7.27)
(7.55)
PAS 2
42.73
50.74
(10.36)
(10.32)
DASS Depression 1
5.18
6.73
(5.25)
(6.29)
DASS Depression 2
4.35
3.55
(3.79)
(4.37)
DASS Anxiety 1
6.00
7.09
(5.90)
(5.65)
DASS Anxiety 2
3.71
4.18
(4.27)
(2.86)
DASS Stress 1
13.76
11.82
(11.35)
(8.22)
DASS Stress 2
9.88
7.18
(8.65)
(6.18)
PCSS 1
28.00
23.80
(15.20)
(23.87)
PCSS 2
22.82
16.45
(17.15)
(17.03)
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A series of mixed factorial ANOVAs were conducted in order to examine the
effects of sex over time on symptom reporting, thus the independent variables were sex
and time. The dependent variables included anxiety, depression, and stress from the
DASS and the PCSS Total symptom score, which were all analyzed in separate tests. A
series of univariate ANOVAs were conducted rather than a multivariate analysis of
variance due to the small sample size and resulting lack of power for the analysis.
Although the implementation of non-parametric statistics may have been better suited to
this data, there was simply not enough power for any significant results to appear. Due to
the small sample size and resulting power, as well as the unequal groups, the results of
the following analyses should be considered exploratory and be interpreted with caution.
PCSS. The first mixed factorial ANOVA was conducted on PCSS scores. Neither
the main effect of time nor of sex was significant [F(1, 25) = 4.00, p = 0.06 and F(1, 25)
= 0.90, p = 0.35, respectively]. Nor was there a significant interaction of sex by time
[F(1, 25) = 0.26, p = 0.62]. The observed power was 0.49 for time, 0.15 for sex, and 0.08
for the interaction effect. Box’s M test, which is used to analyze homogeneity of
variance-covariance matrices, was not significant (7.79, p = 0.71). This suggests that,
despite the hypothesis that females would have higher reports of symptoms on the PCSS,
both sexes typically report stable numbers of symptoms over time when no injury is
incurred.
It was also observed that the PCSS scores in females at time 1 did not significantly
correlate with PCSS scores at time 2 (r = 0.26). Conversely, PCSS scores of male
participants were significantly correlated at time 1 and time 2 (r = 0.87). Given that the
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test has been shown to have adequate test-retest reliability (r = 0.8) it is of note that the
females’ scores were not significantly correlated (ImPACT Application Inc., 2011).
DASS Depression. A 2 (time) x 2 (sex) mixed factorial ANOVA was conducted
on DASS Depression scores. There was a main effect of time [F(1, 26) = 4.46, p = 0.04],
but there was no main effect of sex [F(1, 26) = 0.05, p = 0.82]. The interaction of sex and
time was also not significant [F(1, 26) = 1.55, p = 0.23]. A visual representation of the
results can be seen in Figure 2 below. The observed power was 0.53 for time, 0.06 for
sex, and 0.22 for the interaction effect. Box’s M test was not significant (2.15, p = 0.58).
This suggests that contrary to the hypothesis, females did not report more symptoms of
depression at time 2 than males did. Rather, both sexes reported a decline in symptoms
of depression over time.

Figure 2. DASS Depression by sex and time
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DASS Anxiety. A 2 (time) x 2 (sex) mixed factorial ANOVA was conducted on
the DASS Anxiety subscale. There was a main effect of time [F(1, 26) = 6.12, p = 0.02],
but there was no main effect of sex [F(1, 26) = 0.25, p = 0.62]. The interaction of sex and
time was also not significant [F(1, 26) = 0.09, p = 0.77]. A visual representation of the
results can be seen in Figure 3 below. The observed power was 0.66 for time, 0.08 for
sex, and 0.06 for the interaction effect. Box’s M test was not significant (2.17, p = 0.58).
This suggests that, again, contrary to the hypothesis, females did not report more
symptoms of anxiety at time 2 than males did. Rather, both sexes reported a decline in
symptoms of depression over time.

Figure 3. DASS Anxiety by sex and time
DASS Stress. A 2 (time) x 2 (sex) mixed factorial ANOVA was conducted on the
DASS Stress subscale. There was a main effect of time [F(1, 26) = 5.58, p = 0.03], but no
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main effect of sex [F(1, 26) = 0.59, p = 0.45]. The interaction of sex and time was also
not significant [F(1, 26) = 0.04, p = 0.84]. A visual representation of the results can be
seen in Figure 4 below. The observed power was 0.62 for time, 0.12 for sex, and 0.06 for
the interaction effect. Box’s M test was not significant (2.70, p = 0.48). Once again, the
finding that females did not report more symptoms of stress at time 2 than males did was
contrary to the hypothesis. Both sexes reported a decline in symptoms of stress over
time.

Figure 4. DASS Stress by sex and time
DSRS. A series of paired t-tests were also conducted in the female participants to
determine if there was a significant effect of time on the DSRS Total score and subscales.
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None of the t-tests yielded significant differences between times 1 and 2 (Total: t = 1.97,
p = 0.07; Affective: t = 1.13, p = 0.28; Somatic: t = 2.02, p = 0.06). The DSRS Total was
significantly correlated with itself between times 1 and 2 (r = 0.57, p = 0.02). The
Affective subscale was also significantly correlated with itself between times 1 and 2 (r =
0.70, p < 0.01). The Somatic subscale was not significantly correlated between times 1
and 2 (r = 0.43, p = 0.09). DSRS Total, Affective, and Somatic subscale means and
standard deviations can be seen in Table 3.
Table 3
DSRS Means and Standard Deviations Over Time
Time 1
Total
26.82
(13.29)
Affective subscale
15.24
(7.18)
Somatic Subscale
11.59
(8.09)

Time 2
21.18
(12.30)
13.82
(5.29)
7.35
(8.06)

Differences in Female PCSS Scores
Difference scores between times 1 and 2 on each item of the PCSS were
calculated for the women in order to examine which symptoms in particular were
decreasing over time. The top five symptoms that decreased at time 2 from reports at time
1, which all decreased 10 or more points overall, in descending order were “irritability”,
“feeling more emotional”, “sadness”, “drowsiness”, and “sleeping more than usual”.
However, only “irritability” was significantly different at time 2 (t = 2.67, p = 0.02) and
the rest of the symptoms had p values above the 95 th percent confidence interval
(remaining p’s = 0.23, 0.10, 0.19, 0.28, respectively). The only symptoms that actually
increased at time 2 were, in order of largest increase to smallest, “numbness or tingling”,
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“difficulty remembering”, and then “feeling like ‘in a fog’ ” and “nervous/anxious”.
None of these increases were significant (p’s = 0.56, 0.67, 0.89, 0.86, respectively). No
other PCSS symptoms were statistically significantly different between the time points.
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CHAPTER 4
DISCUSSION
This study examined the relationships between reports of symptoms commonly
associated with the menstrual cycle, and also those associated with incurring a
concussion, over time. There were three main hypotheses that were explored and each
will be discussed below.
PCS and Menstrual Symptom Correlations
The first hypothesis was that the number and severity of PCS symptoms reported
would correlate at each point in time with the number and severity of menstrual
symptoms reported in women. This hypothesis was investigated by examining the
correlations between the PCSS Total score, DSRS Total score, DSRS Somatic subscale,
and DSRS Affective subscale scores. At time 1 the PCSS Total correlated significantly
with all three DSRS scores, therefore the hypothesis was supported at time 1. At time 2,
the PCSS Total significantly correlated with all three DSRS scores. Thus, the hypothesis
was also supported at time 2. It is interesting to note that PCSS and DSRS scores were
more significantly correlated at time 2 (r = .58 at time 1 vs. r = .88 at time 2), when it
was predicted that symptom reports on these questionnaires would be higher due to the
increasing concentrations of female sex hormones. Fisher’s Z-transformation was
calculated, revealing a z score of 1.89, p = 0.03 for a one-tailed test. A one-tailed test was
used due to the prediction that symptom reports on these questionnaires would be higher
due to the increasing concentrations of female sex hormones. Perhaps there is some effect
of menstrual phase, or the underlying sex hormones, that resulted in stronger correlations.
Effect of Menstrual Phase
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It was hypothesized that women would experience fewer and less severe affective
and somatic symptoms during their first testing session, occurring during the follicular
phase, and more affective and somatic symptoms during the second testing session,
which occurred in the luteal phase, as concentrations of both estrogen and progesterone
are increased compared with during the follicular phase, and symptoms typically decline
at the onset of menstruation (Backstrom et al., 1983). It was also hypothesized that male
symptom reports would remain constant over time, thus resulting in an interaction effect.
This hypothesis was not supported given that all of the symptom reports decreased at the
second testing session, although not all of the decreases were statistically significant.
Further, the interactions between the time points and genders on the participants’ scores
on the PCSS, the DASS Depression, the DASS Anxiety, and the DASS Stress subscales
were not significant. This finding was not expected, but has the positive implication that
use and comparison of these measures in females at various points in the menstrual cycle
may be appropriate should these results be replicated with a larger and more
representative sample. However, the observed power for these analyses related to sex
were low, 0.15, 0.06, 0.08, and 0.12 for the PCSS, DASS Depression, DASS Anxiety,
and DASS Stress subscales, respectively. With stronger power a potential main effect of
sex may emerge. Relatedly, the observed power for the analyses related to the interaction
of sex and time point were also quite low. On the PCSS power was 0.08, on the DASS
Depression subscale it was 0.22, on the DASS Anxiety subscale it was 0.06, and on the
DASS Stress subscale it was 0.06. Again, with stronger power there may emerge an
interaction effect.
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Reasons for these unexpected results may be partially explained by a number of
factors. Having the male sample included in the study was helpful for interpreting these
results because males do not experience a similar monthly cycle to females. As the males
also showed a similar decrease in the number and severity of symptoms they reported, it
suggests that the decreases in symptoms over time were not due to changes in sex
hormones, but rather some other factor. Further, participants were tested at the same time
of day, so daily hormonal fluctuations can be ruled out as culprits for changing levels of
symptoms. In addition, participant data was collected over three semesters (winter,
interim, and summer), thus time of academic year, and corresponding life stressors,
should not have been a confounding factor in this study. Although, perhaps simply being
further along in a semester influences students’ affect and symptom presentation, as the
second part of the assessment always occurred two weeks after the first.
Despite the fact that many of the symptoms measured are associated with
hormonal changes over the course of the menstrual cycle, it is also possible that this study
did not measure symptoms at the most opportune times to pick up differences. Female
participants completed part one of the study about five to seven days after the onset of
their last menstrual period, and the second part of the study was thus completed about day
19 to 21 of their cycles. Many of the symptoms measured may be more likely to increase
in severity later in the luteal phase (i.e. when “premenstrual syndrome” occurs) then
when measurement took place. Most symptoms thought to occur as part of the
“premenstrual syndrome” only occur in the days leading up to the onset of menstruation,
and potentially in the first 2-3 days of menstruation (Romans et al., 2012). It may have
been better to have participants come back a few days later for their second assessment,

36

MENSTRUAL PHASE & PCS SYMPTOM REPORTING
but due to differing schedules on different days of the week, it was thought that it would
facilitate participation in the study better if appointments took place of the same day of
the week, as it was desired to have participants return at the same time of day, due to
daily fluctuations in hormones. It was further desired to keep the day of the week
constant in case of any effects of the day of week on symptoms, in case, for example,
participants were more fatigued later in the week due to attending early classes or work
schedules.
Despite the lack of significant interaction between time and gender on PCSS
symptoms, there are potential clinical implications. If this finding is replicable with a
larger sample size, it suggests that it is appropriate to compare baseline symptom reports
of females obtained in one menstrual phase with post-concussive symptom reports from a
different menstrual phase without concern for elevations in number and severity of
symptoms due to the menstrual cycle. That said, the different symptoms were only
examined at the item level in a cursory way in this study. It is possible that the particular
symptoms or types of symptoms reported may differ over time, which may be related to
menstrual phase.
Relatedly, it was observed that scores on the PCSS in males were significantly
correlated between time 1 and time 2 (r = 0.87) but we not significantly correlated for
females (r = 0.26). While the number and severity of symptoms in the overall female
sample was found not to significantly differ between time points, their scores at time 2
were not related to their scores at time 1, whereas male scores were similar to each other.
This suggests that perhaps there is some effect of female sex hormones on the presence of
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different symptoms at different points in the menstrual cycle rather than simply
influencing the overall number and severity of symptoms.
Oral Contraceptive Use
Given the statistical limitations due to the small sample size, it is not surprising
that no group differences were observed between women who do and no not use oral
contraceptives (eumenorrheic women = 9 and oral contraceptive users = 8). As oral
contraceptive pills are commonly prescribed to help decrease the symptoms of
menstruation, the use of these pills may mask the individuals who would otherwise
experience more different and more severe menstrual symptoms. However, we were
unable to observe any possible effects due to limitations on statistical power related to the
small sample sizes.
Limitations and Future Direction of Research
There are a number of limitations to the current study, the first and most evident
being the small sample size included in the analyses. As a result of this small sample size,
many of the analyses were under-powered. Conducting a similar study with an adequate
number of participants may yield different results. In addition, the sample's demographics
were determined through the participant pool sign up process. The results of this study
may not be generalizable to non-university students, or people who did not fall into the
age range of those who participated.
This study also sought to use physical activity as a covariate in analyses. Physical
activity has been shown to affect the presence of the symptoms measured on the PCSS
(Malleck, Richardson, Considine & Abeare, Manuscript in preparation). Due to the
inconsistent reporting on the PAS, the integrity of this variable was not ideal. Participants
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were likely more accurate at rating certain levels of activity rather than others. For
example, the estimate for the number of hours they slept will likely be more accurate than
the number of hours spent “standing, washing dishes or cooking, driving a car or truck”
because the latter activities are often completed for shorter amounts of time and more
often, making them more difficult to estimate than activities completes during one longer
period of time, such as sleeping. PAS scores were calculated based on the percent of
hours reported on the questionnaire, so the scores may have underestimated the total level
of activity by participants due to underreporting of various activities while awake. Future
research should further investigate the use of physical activity as a covariate with a larger
sample size and more accurately measured.
When data was collected for this study the titles of the questionnaires were
included due to copyright restrictions. It is unknown if participant responding was
influenced by these titles. For example, it is possible that participants may have
underrated symptoms on the PCSS due to the fact that they saw the word “concussion”
and had not recently incurred a concussion and thus did report the presence of symptoms
on this questionnaire. In future research it is advisable to remove any such titles so as to
remove the possibility of biasing participant responding.
Another limitation of this study was that hormone concentrations were estimated,
not directly measured. Future research could use salivary or core temperature
measurements to get more accurate appraisals of menstrual phase.
Further, this study measured just two time points during the menstrual cycle.
These time points were chosen as estrogen and progesterone were at different
concentrations, but hormones vary continuously over the cycle, which may indicate
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different concentrations of symptomatology that were not picked up on in this study. One
particular time point of interest may be ovulation, after which estrogen concentrations
rapidly fall. This study was not able to precisely isolate the time of ovulation due to lack
of availability of direct measures of hormone concentrations. It would also be interesting
to measure symptomatology later in the luteal phase, when “premenstrual syndrome” is
thought to occur.
Relatedly, the same menstrual phase (follicular) was consistently measured first,
as it was believed it would be easier to facilitate participant sign-up requesting first
sessions take place 5-7 days after the onset of participants’ last menstrual period rather
than some longer period, or asking them to come in a certain number of days before their
next menstrual period as they may not have known exactly when it would occur. It was
feared that longer time intervals between a noticeable event (i.e. onset of menses) would
introduce more variability regarding when during their menstrual cycles the females
participated. Ideally, phase during the menstrual cycle when measurements took place
would have also been counterbalanced to reduce any bias related to test-retest effects.
Finally, as mentioned above, this study looked simply at the number of symptoms
endorsed at two different time points in the menstrual cycle rather than examining in
detail which symptoms in particular, or types of symptoms (e.g. somatic, cognitive), that
were endorsed at each time point. This would be of particular interest given the finding
that female scores on the PCSS were not statistically significantly correlated between the
time points, but the male scores were. Future research could examine the specific
symptoms individually to determine if there is a difference in the particular types
symptoms that are reported at different times over the menstrual cycle.
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CHAPTER 5
CONCLUSIONS
This study represents an effort toward elucidating the contributing factors of
menstrual phase and female sex hormones toward baseline and post-concussive
neuropsychological symptoms. The results of this study indicated that female and male
symptom reports were similar at different time points in the females’ menstrual cycles in
terms of number and severity of symptoms. The implication of these findings is that it
does appear to be appropriate to compare female baseline symptom reports obtained in
one menstrual phase to post-concussive symptom reports obtained from a different
menstrual phase without concern that the number and severity of symptoms are due to
variance in female sex hormones rather than due to the effects of the incurred mTBI.
With that said, many analyses lacked power and there were also some preliminary
indications that the type of symptoms experienced by women may vary over the course of
the menstrual cycle. More detailed examination of types of symptoms experienced over
the menstrual cycle is warranted.
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APPENDIX A
The Post-Concussion Symptom Scale (PCSS)
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Instructions Given for the PCSS
Please complete the paper questionnaire you were given at this time. Please indicate the
level for which you are CURRENTLY experiencing the symptoms listed, as per the scale
on the paper. So, you should only fill out one column with your ratings for today. Do not
worry about writing the date or calculating the total. When you are finished please return
to this page and click next.
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APPENDIX B
DEPRESSION ANXIETY STRESS SCALES (DASS)

54

MENSTRUAL PHASE & PCS SYMPTOM REPORTING

55

MENSTRUAL PHASE & PCS SYMPTOM REPORTING

56

MENSTRUAL PHASE & PCS SYMPTOM REPORTING

57

MENSTRUAL PHASE & PCS SYMPTOM REPORTING

Depression Anxiety Stress Scales
Source:
Lovibond, P. F., & Lovibond, S. H. (1995). The structure of negative emotional states:
Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression
and Anxiety Inventories. Behaviour Research and Therapy, Vol 33(3), 335-343. doi:
10.1016/0005-7967(94)00075-U, © 1995 by Elsevier. Reproduced by Permission of
Elsevier.
Permissions:
Test content may be reproduced and used for non-commercial research and educational
purposes without seeking written permission. Distribution must be controlled, meaning
only to the participants engaged in the research or enrolled in the educational activity.
Any other type of reproduction or distribution of test content is not authorized without
written permission from the author and publisher. Always include a credit line that
contains the source citation and copyright owner when writing about or using any test.
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APPENDIX C
PHYSICAL ACTIVITY SCALE (PAS)
How physically active are you on an average weekday?
In the physical activity scale you see some examples of different levels of physical activity. Try to assess
how much time you spend on each level on an average weekday. Start with level A and continue
downward.
If you normally sleep 7 hours, you should mark the 7-h box of level A. If you watch TV for an hour and a
half, you should mark the 30-min box and the 1-h box of level B. If you are not active on all activity levels,
you should leave levels unmarked.
Please note that the total number of minutes and hours should amount to 24  an average weekday and
night. You may find the column on the right helpful when adding the minutes and hours together
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APPENDIX D
DAILY SYMPTOM RATING SCALE (DSRS)
Please record your experience during this day of the feelings and sensations listed below.

Daily Questions
0
not at all

1) Hopelessness
2) Depression
3) Lack of initiative
4) Withdrawal
5) Tension
6) Irritability
7) Argumentativeness
8) Cheerfulness
9) Outgoingness
10) Energy
11) Breast swelling or
tenderness
12) Abdominal swelling
13) Swelling of face, hands,
ankles
14) Pelvic or abdominal
pain
15) Backache
16) Headache
17) Tiredness

1
very little

2
little

3
moderate
amount

4
large
amount

5
very large
amount
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alter, remove or suppress in any manner any copyright, trademark or other notices displayed by
the Wiley Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, transfer
or assign the Wiley Materials on a stand-alone basis, or any of the rights granted to you hereunder
to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times remain the
exclusive property of John Wiley & Sons Inc, the Wiley Companies, or their respective licensors,
and your interest therein is only that of having possession of and the right to reproduce the Wiley
Materials pursuant to Section 2 herein during the continuance of this Agreement. You agree that
you own no right, title or interest in or to the Wiley Materials or any of the intellectua l property
rights therein. You shall have no rights hereunder other than the license as provided for above in
Section 2. No right, license or interest to any trademark, trade name, service mark or other
branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree that you shall
not assert any such right, license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS,
IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE ACCURACY
OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT
LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY,
SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEM ENT AND ALL SUCH WARRANTIES ARE HEREBY
EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.
WILEY shall have the right to terminate this Agreement immediately upon breach of this
Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective
directors, officers, agents and employees, from and against any actual or threatened claims,
demands, causes of action or proceedings arising from any breach of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER
PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIA L,
INCIDENTA L, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED,
ARISING OUT OF OR IN CONNECTION WITH THE DOWNLOADING, PROVISIONING,
VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEM ENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS
OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT THE PARTY
HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION
SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY PROVIDED HEREIN.
Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal,
invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible
the same economic effect as the original provision, and the legality, validity and enforc eability of
the remaining provisions of this Agreement shall not be affected or impaired thereby.
The failure of either party to enforce any term or condition of this Agreement shall not constitute a
waiver of either party's right to enforce each and every term and condition of this Agreement. No
breach under this agreement shall be deemed waived or excused by either party unless such waiver
or consent is in writing signed by the party granting such waiver or consent. The waiver by or
consent of a party to a breach of any provision of this Agreement shall not operate or be construed
as a waiver of or consent to any other or subsequent breach by such other party.
This Agreement may not be assigned (including by operation of law or otherwise) by you without
WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days from receipt by
the CCC.
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These terms and conditions together with CCC's Billing and Payment terms and conditions (which
are incorporated herein) form the entire agreement between you and WILEY concerning this
licensing transaction and (in the absence of fraud) supersedes all prior agreements and
representations of the parties, oral or written. This Agreement may not be amended except in
writing signed by both parties. This Agreement shall be binding upon and inure to the benefit of
the parties' successors, legal representatives, and authorized assigns.
In the event of any conflict between your obligations established by these terms and conditions
and those established by CCC's Billing and Payment terms and conditions, these terms and
conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i) the license
details provided by you and accepted in the course of this licensing transaction, (ii) these terms
and conditions and (iii) CCC's Billing and Payment terms and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was
misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of the State of
New York, USA, without regards to such state's conflict of law rules. Any legal action, suit or
proceeding arising out of or relating to these Terms and Conditions or the breach thereof shall be
instituted in a court of competent jurisdiction in New York County in the State of New York in the
United States of America and each party hereby consents and submits to the personal jurisdiction
of such court, waives any objection to venue in such court and consents to service of process by
registered or certified mail, return receipt requested, at the last known address of such party.
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Malayna Malleck was born in 1991 in Kitchener, Ontario. She graduated from WaterlooOxford District Secondary School in 2009. From there she went on to York University
where she obtained a B.A. in psychology in 2013. She is currently a candidate for the
Master's degree in Clinical Neuropsychology at the University of Windsor and hopes to
graduate in Fall 2016.

65

